Richard Woodrich

Outsourcing Solutions, Inc. provides business process outsourcing services. The firm specializes in accounts receivable management services. Its services include asset-backed securities, distressed debt portfolio management, post-charge off recovery, portfolio acquisition & management, legal network management and bankruptcy services. Outsourcing Solutions was founded in 1995 and is headquartered in Chesterfield, MO.

OrbiMed Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. It was founded by Sven Borho and Carl Gordon in 1989. The firm provides discretionary investment management services to US and non-US public and private funds.

ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Arteaus Therapeutics LLC develops therapies for migraine prevention. The company was founded by Dave Grayzel and Scott C. Chappel on July 15, 2011 and is headquartered in Cambridge, MA.

Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA.

Oxeia Biopharmaceuticals, Inc. is a clinical-stage biotech company, which develops new, innovative therapies for conditions that are defined by deficits in neurocognition from injury, degeneration and aging. Its two indications are for (i) mild traumatic brain injury (?mTB?) known as concussion, and (ii) the cognitive decline, lethargy and ?brain-fog? associated with Covid-19 infection, known as Covid Longhauler syndrome (?Long Covid?). The company was founded in 2014 by Vishal Bansal, Amit Dilip Munshi & Kartik Kiran Shah and is headquartered in Boston, MA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Adnexus engages in the development of Adnectins biologics and medicines in the United States. The company was founded by Frank D. Lee on September 16, 2002 and is headquartered in Waltham, MA.

Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools.

Limulus Management Co. LLC is a venture capital firm founded by Lawrence Miller and Paul Howard in 1999. It is headquartered in Newton, Massachusetts.

Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada.

OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.

Bristol-Myers Squibb SARL engages in the research, development, manufacture, and distribution of pharmaceutical products. Its therapeutic areas include immunoscience, immune-oncology, and cardiology. The company is headquartered in Rueil-Malmaison, France.

NeuroHealing Pharmaceuticals, Inc. develops drug therapies for the post-acute and chronic neuro-rehabilitation patients. Its products include NH001, a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative, or minimally consciousness state, NH004, a treatment for the social debilitating condition of sialorrhea, a non-motor complaint of Parkinson's disease patients and NH02D, an orally administered drug for on-demand treatment of premature ejaculation, a male sexual disorder affecting sexually active men. The company was founded by Esteban Fridman and Daniel Katzman in 2003 and is headquartered in Waban, MA.

PA Consulting Group, Inc. provides management consulting services. The company is headquartered in New York, NY.

SRI Consulting, Inc. provides information technology and business support services. It specializes in the development, implementation and maintenance of software solutions. The company was founded by Philip C. Sharpe in 1995 and is headquartered in Fairfax, VA.

Part of Arrowhead Pharmaceuticals, Inc., Alvos Therapeutics, Inc. develops novel cancer drugs. The company is based in Wellesley, MA. The company was founded by Mark Wayne Leuchtenberger. Alvos Therapeutics was acquired by Arrowhead Pharmaceuticals, Inc. on April 11, 2012 for $25.50 million.

GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada.

Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA.

Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA.

Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million.

Aleta Biotherapeutics, Inc. engages in the immuno-oncology service that focuses on transforming cellular therapeutics. It allows broad spectrum of cancer indication to be targeted including currently intractable solid tumors. The company was founded by Paul Rennert and Roy Lobb and is headquartered in Natick, MA.

Endlyz Therapeutics, Inc. is an American company that operates in the biotechnology industry.